The COPD biomarker qualification consortium (CBQC)

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 3, 2013, Pages 367-377

  Casaburi, Richard ^a   Celli, Bartolome ^b   Crapo, James ^b   Criner, Gerard ^c   Croxton, Thomas ^d   Gaw, Alasdair ^e   Jones, Paul ^f   Kline Leidy, Nancy ^g   Lomas, David A ^h   Merrill, Debora ⁱ   Polkey, Michael ^j   Rennard, Stephen ^k   Sciurba, Frank ^l   Tal Singer, Ruth ^m   Stockley, Robert ⁿ   Turino, Gerry ^o   Vestbo, Jorgen ^p   Walsh, John ⁱ  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e Technology Strategy Board   (United Kingdom)

^f UNIVERSITY OF LONDON   (United Kingdom)

^g United BioSource Corporation   (United States)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ National Bronchiectasis Research Registry   (United States)

^j ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^m GLAXOSMITHKLINE   (United States)

ⁿ UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^o Och Spine at New York Presbyterian Hospitals   (United States)

^p UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

Biomarker; Biomarker qualification; CBQC; COPD Exacerbations; COPD foundation; Desmosine; Exercise; Exhaled breath biomarkers; Fibrinogen; Imaging; Patient reported outcomes; Six minute walk test; Sputum measures; St. George's respiratory questionnaire

Indexed keywords

C REACTIVE PROTEIN; CLARA CELL PROTEIN; CORTICOSTEROID; DESMOSINE; ELASTIN; FIBRINOGEN; SERUM AMYLOID A; SURFACTANT PROTEIN D; TIOTROPIUM BROMIDE;

AMINO ACID BLOOD LEVEL; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDUSTRY; EXERCISE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH STATUS; HUMAN; LUNG MECHANICS; MUSCLE STRENGTH; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DESMOSINE; DISEASE PROGRESSION; EXERCISE TEST; FIBRINOGEN; HEALTH STATUS; HUMANS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; RESPIRATORY MECHANICS; SEVERITY OF ILLNESS INDEX; SPUTUM; TREATMENT OUTCOME; UTEROGLOBIN;

EID: 84878472359     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.752807     Document Type: Article

References (50)

1. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the fi rst decade, 2000-2009. Clin Pharmacol Th erapeut 2011; 89:183-188.
2. Woodcock J, Woosley R. Th e FDA critical path initiative and its infl uence on new drug development. Annu Rev Med 2008; 59:1-12.
3. FDA. Guidance for Industry Qualifi cation Process for Drug Development Tools. 2010.
4. FDA. Strategic Priorities: Cross-Cutting Strategic Priorities. http://www. fda. gov/aboutFDA/Reportsmanualsforms/Reports/ucm246737. htm
5. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:250-255.
6. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fi brinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1008-1111.
7. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway infl ammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-13.
8. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867-74.
9. Bozinovski S, Hutchinson A, Th ompson M, et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:269-78.
10. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Th orax 2008; 63:1058-63.
11. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009; 34:95-102.
12. Sin DD, Man SF, Marciniuk DD, et al. Th e eff ects of fl uticasone with or without salmeterol on systemic biomarkers of infl ammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:1207-1214.
13. Sin DD, Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc Am Th orac Soc 2009; 6:543-545.
14. Danesh J, Lewington S, Th ompson SG, et al. Plasma fi brinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant metaanalysis. JAMA 2005; 294:1799-1809.
15. Barnes NC, Pavord ID, Maden C, Gomez E, Keene O, Tal-Singer R. Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD. Eru Resp J 2009; 34(sup):544s.
16. Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fi brinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2012; 52:416-424.
17. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11:122.
18. Bergin C, Muller N, Nichols DM, et al. Th e diagnosis of emphysema. A computed tomographic-pathologic correlation. Am Rev Respir Dis 1986; 133:541-546.
19. Muller NL, Staples CA, Miller RR, Abboud RT. "Density mask". An objective method to quantitate emphysema using computed tomography. Chest 1988; 94:782-787.
20. Gevenois PA, De Vuyst P, Sy M, et al. Pulmonary emphysema: quantitative CT during expiration. Radiology 1996; 199:825-829.
21. Hasegawa M, Nasuhara Y, Onodera Y, et al. Airfl ow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:1309-1315.
22. Patel BD, Coxson HO, Pillai SG, et al. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178:500-505.
23. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: A randomised study of augmentation therapy in alpha-1 antitrypsin defi ciency. Euro Respir J 2009; 33:1345-1353.
24. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160:1468-1472.
25. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-2073.
26. Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly LJ, Celli BR. Th e 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest 2007; 132:1778-1785.
27. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167:544-549.
28. Spruit MA, Polkey MI, Celli B, et al. Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc 2012; 13:291-297.
29. Celli BR, Cote CG, Marin JM, et al. Th e body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012.
30. Gremeaux V, Troisgros O, Benaim S, et al. Determining the minimal clinically important diff erence for the six-minute walk test and the 200-meter fast-walk test during cardiac rehabilitation program in coronary artery disease patients after acute coronary syndrome. Arch Phys Med Rehabil 2011; 92:611-619.
31. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fi brosis: test validation and minimal clinically important diff erence. Am J Respir Crit Care Med 2011; 183:1231-1237.
32. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012; 126:349-356.
33. Seymour JM, Spruit MA, Hopkinson NS, et al. Th e prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010; 36:81-88.
34. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140:331-342.
35. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:972-977.
36. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: Compliance and associations with clinical characteristics in a multicenter study. Respir Med 2012; 106:522-530.
37. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32:1146-1157.
38. Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184:637-641.
39. Chrzanowski P, Keller S, Cerreta J. Elastin content of normal and emphysematous lung parenchyma. Am J Med 1988; 69:351-359.
40. Wright RR. Elastic tissue of normal and emphysematous lungs: a tridimensional histological study. Am J Pathol 1961; 39:355-363.
41. Ma S, Lieberman S, Turino GM, Lin YY. Th e detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum. Proc Natl Acad Sci USA 2003; 100:12941-12943.
42. Ma S, Turino GM, Lin YY. Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:1893-1898.
43. Ma S, Lin YY, Turino GM. Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest 2007; 131:1363-1371.
44. Fregonese L, Ferrari F, Funagalli M, Luisetti M, Stolk J, Iadarola P. Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antitrypsin defi ciency-related COPD. J COPD 2011; 3:229-333.
45. Lindberg CA, Engstrom G, de Verdier MG, et al. Total desmosines in plasma and urine correlate with lung function. Eur Respir J 2012; 39:839-845.
46. Ma S, Lin YY, Tartell L, Turino GM. Th e eff ect of tiotropium therapy on markers of elastin degradation in COPD. Respir Res 2009; 10:12.
47. Montuschi P. Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. Th er Adv Respir Dis 2007; 1:5-23.
48. Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008; 32:472-486.
49. Eff ros RM, Casaburi R, Su J, et al. Th e eff ects of volatile salivary acids and bases on exhaled breath condensate pH. Am J Respir Crit Care Med 2006; 173:386-392.
50. Eff ros RM, Casaburi R, Porszasz J, Rehan V. Why conventional exhaled breath condensate pH studies cannot provide reliable estimates of airway acidifi cation. Chest 2011; 140:1099.